NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
Goldman Sachs downgraded Regenxbio Inc (NASDAQ:RGNX), citing gene therapy’s appeal for wet AMD and diabetic retinopathy is ...
Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback